Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -140.8%. (2017–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | — | — | — | — | — | — | — | — |
| Enterprise Value | $-4895 | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.14 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.40 | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -140.8% | -140.8% | — | -862.9% | -2202.5% | — | — | — | — |
| ROA | -97.1% | -97.1% | -218.9% | -219.3% | -342.5% | -299.9% | -1293.8% | -0.4% | -290.9% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | -311.5% | -311.5% | — | -333.7% | -352.9% | — | — | — | -444.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.18 | — | -2.73 | -10.01 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -24.24 | -24.24 | -81.34 | -153.49 | -174.33 | -11.24 | -5.65 | -3.18 | -6.48 |
Net cash position: cash ($2M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.69 | 2.69 | 0.23 | 2.75 | 2.38 | 0.03 | 0.09 | 0.04 | 2.30 |
| Quick Ratio | 2.69 | 2.69 | 0.23 | 2.76 | 2.40 | 0.04 | 0.09 | 0.04 | 2.30 |
| Cash Ratio | 2.01 | 2.01 | 0.11 | 2.66 | 2.26 | 0.01 | 0.05 | 0.00 | 2.21 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $154328 | $4M | $2M | $1M | $481928 | $1M | $16 | $1M |
Imminent liquidity exhaustion
Based on reported figures, NCEL trades at a price-to-book ratio of 0.42, which suggests the market assigns minimal value to the company's intellectual property relative to its historical cost, reflecting deep skepticism regarding the firm's ability to achieve a successful clinical or commercial milestone.
The current P/B multiple indicates that the market is pricing the company as a distressed asset rather than a going concern. Investors should monitor whether this valuation gap represents a genuine opportunity for acquisition or a rational assessment of the high probability of total equity impairment.
According to recent financial statements, NCEL's current ratio of 2.77 appears deceptively healthy, yet this figure masks a critical lack of absolute cash reserves, with only $1.66M available to support ongoing research and administrative obligations in a high-burn environment.
While the current ratio suggests an ability to cover short-term liabilities, the absolute dollar amount of liquidity is insufficient to sustain operations beyond the immediate term. This suggests that the company is highly vulnerable to any disruption in its ability to access external capital markets.
As reported in historical data, NCEL's days payable outstanding has fluctuated wildly, reaching 35,299 days in 2025Q2, which suggests that the company is likely deferring payments to vendors to preserve its dwindling cash position rather than operating with standard working capital efficiency.
Such extreme volatility in DPO is rarely a sign of operational strength and instead points to a desperate attempt to manage cash timing. This behavior warrants further investigation, as it may indicate strained relationships with suppliers or an inability to meet contractual obligations on a timely basis.
The price-to-earnings ratio is the most commonly misapplied metric for NCEL, as the company's negative earnings profile renders traditional valuation multiples meaningless and obscures the reality that the firm's survival depends entirely on its cash runway rather than its current profitability.
Analysts should instead focus on the 'Net Burn Rate' and 'Cash Runway' to assess the company's viability. Using P/E or other earnings-based ratios in this context is misleading because it implies a level of operational maturity that simply does not exist for this pre-revenue entity.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NCEL stock.
NewcelX Ltd.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
NewcelX Ltd.'s return on equity (ROE) is -140.8%. The historical average is -140.8%.
Based on historical data, NewcelX Ltd. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.